Drug Type Therapeutic radiopharmaceuticals |
Synonyms MNPR-101-PCTA-177Lu |
Target |
Mechanism uPAR modulators(Urokinase plasminogen activator surface receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 1 | AU | 01 Oct 2024 | |
Colorectal Cancer | Phase 1 | AU | 01 Oct 2024 | |
Lung Cancer | Phase 1 | AU | 01 Oct 2024 | |
Ovarian Cancer | Phase 1 | AU | 01 Oct 2024 | |
Pancreatic Cancer | Phase 1 | AU | 01 Oct 2024 | |
Stomach Cancer | Phase 1 | AU | 01 Oct 2024 | |
Triple Negative Breast Cancer | Phase 1 | AU | 01 Oct 2024 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 1 | AU | 01 Oct 2024 |